Current Open Trials
The below clinical trials are being pulled directly from clinicaltrials.gov. These are open trials that are from the last 365 days.
ClinicalTrials.gov: Open Studies | Mesothelioma
Studies received in the last 14 days and found by a search of: Open Studies | Mesothelioma
last updated: Jul 24 2008 8:29 AM
- Mesothelioma Avastin Plus Pemetrexed-Cisplatin Study
Condition: Mesothelioma
Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin); Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
Sponsors: Intergroupe Francophone de Cancerologie Thoracique; CHU de Caen; Groupe Francais de Pneumo-Cancérologie; European Lung Cancer Working Party
Recruiting - verified April 2008 - Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Procedure: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified March 2008 - A Study To Find the Best Dose of SU011248 When Given With Pemetrexed, Pemetrexed and Cisplatin Or Pemetrexed and Carboplatin in Patients With Advanced Solid Tumors
Conditions: Non-Small Cell Lung Cancer; Mesothelioma; Neoplasms
Intervention: Drug: Sunitinib, Pemetrexed, Cisplatin, Carboplatin
Sponsor: Pfizer
Recruiting - verified July 2008 - Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
Conditions: Malignant Epithelial Mesothelioma; Adenocarcinoma of the Pancreas; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma of the Ovaries
Intervention: Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
Sponsor: Anza Therapeutics, Inc.
Recruiting - verified April 2008 - Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified June 2008 - Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With MPM
Condition: Mesothelioma
Intervention: Drug: Carboplatin, Bevacizumab and Pemetrexed
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Genentech
Recruiting - verified January 2008 - N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
Conditions: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell Lung; Mesothelioma
Interventions: Drug: N-Acetylcysteine; Drug: Placebo
Sponsor: Rijnstate Hospital
Not yet recruiting - verified March 2008 - Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
Conditions: Soft Tissue Sarcoma; Mesothelioma
Intervention: Drug: Azacitidine In Combination With Temozolomide
Sponsors: Columbia University; Schering-Plough; Pharmion
Recruiting - verified February 2008 - Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
Conditions: Carcinoma, Non-Small-Cell Lung; Mesothelioma
Intervention: Drug: LBH 589
Sponsor: Novartis
Recruiting - verified July 2008 - Extrapleural Pneumonectomy, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Procedure: Extrapleural pneumonectomy (EPP); Drug: cisplatin; Drug: gemcitabine; Drug: amifostine; Drug: sodium thiosulfate
Sponsors: Brigham and Women's Hospital; Dana-Farber Cancer Institute
Recruiting - verified December 2007 - A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Imatinib mesylate plus Gemcitabine
Sponsor: Gruppo Italiano MEsotelioma
Not yet recruiting - verified October 2007 - Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: OSI-930 and erlotinib
Sponsor: OSI Pharmaceuticals
Recruiting - verified June 2008 - A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin
Sponsors: Norris Comprehensive Cancer Center; Sponsor Name Pending
Not yet recruiting - verified April 2008 - Study Using Chemotherapy Followed by Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced But Unresectable Malignant Pleural Mesothelioma
Condition: Mesothelioma
Intervention: Other: Pemetrexed + Cisplatin and Intensity Modulated Radiation Therapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company
Recruiting - verified July 2008 - An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Milataxel
Sponsor: Taxolog Inc.
Recruiting - verified May 2008 - Study of CBP501 + Pemetrexed + Cisplatin in Patients With Solid Tumors (Phase I) and Patients With Malignant Pleural Mesothelioma (Phase II)
Conditions: Malignant Pleural Mesothelioma; MPM; Solid Tumors
Interventions: Drug: pemetrexed, cisplatin and CBP501; Drug: pemetrexed and cisplatin
Sponsor: CanBas Co. Ltd.
Recruiting - verified June 2008 - Dasatinib in Resectable Malignant Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb; Department of Defense
Recruiting - verified April 2008 - Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: Valproate plus doxorubicin
Sponsor: European Lung Cancer Working Party
Recruiting - verified March 2008 - An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Vinorelbine; Drug: Vandetanib
Sponsor: AstraZeneca
Recruiting - verified April 2008 - Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: vitamin B12; Procedure: gene expression analysis; Procedure: laboratory biomarker analysis; Procedure: pharmacological study
Sponsor: Centre Oscar Lambret
Recruiting - verified October 2007 - Immunotoxin Therapy, Pemetrexed, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed by Surgery
Condition: Malignant Mesothelioma
Interventions: Drug: SS1(dsFv)-PE38 immunotoxin; Drug: cisplatin; Drug: pemetrexed disodium; Procedure: immunoenzyme technique; Procedure: immunohistochemistry staining method; Procedure: pharmacological study; Procedure: quality-of-life assessment
Sponsor: National Cancer Institute (NCI)
Recruiting - verified March 2008 - Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: bortezomib; Procedure: quality-of-life assessment
Sponsor: Irish Clinical Oncology Research Group
Recruiting - verified August 2007 - Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
Condition: Malignant Mesothelioma
Interventions: Drug: dasatinib; Procedure: immunoenzyme technique; Procedure: immunohistochemistry staining method; Procedure: laboratory biomarker analysis
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified July 2008